ONE-PEAK
6.12.2022 11:15:36 CET | Business Wire | Press release
One Peak, a leading investor for growth stage B2B software companies in Europe and Israel, is excited to announce the closing of One Peak Growth III at its hard cap of $1 billion. The fund was significantly oversubscribed, demonstrating strong LP demand. Building on the success of One Peak’s first two funds, the closing of One Peak Growth III brings the firm’s total assets under management to c. $2 billion. The size of the new fund makes One Peak, founded by David Klein and Humbert de Liedekerke Beaufort, the largest fund in Europe dedicated to backing fast growing B2B software companies in the $15m-$100m investment range.
Accelerating Growth
Humbert de Liedekerke Beaufort, Co-founder and Managing Partner, said: “Growth equity is a significantly underrepresented asset class in Europe versus the US and China. There are many world class founders in Europe who need capital and support to win at global scale, and One Peak fills that gap for the best B2B software companies. With Fund III, we’ll continue to partner with the most ambitious founders and support them with our sector expertise, global network, and value creation platform to build enduring companies against the backdrop of today’s macroeconomic headwinds. $15-100m is our investment sweet spot, where we act as a catalyst to accelerate growth and help companies realize their full potential.”
Deep B2B Sector Expertise
Over the past 8 years, One Peak has built a concentrated portfolio of minority stakes in category leading software companies such as Cymulate, Deepki, DocPlanner, PandaDoc, Neo4j, and Spryker Systems. The One Peak team is an active partner to the founders it backs and supports them in building lasting, category-defining companies for the long term. This includes access to some of the best B2B software operators in the world through One Peak’s Value Creation Team which is comprised of experts in sales, marketing, partnerships, product, tech, and talent.
David Klein, Co-founder and Managing Partner, said: “We are ultimately in the business of investing in exceptional founders, and we work alongside them with the same passion and dedication as they do. Our value-add is significantly enhanced by our fully integrated Value Creation Team, particularly when it comes to hiring the best talent, accelerating top line growth, driving global expansion, and improving product and technology capabilities. This is a key differentiator for our portfolio companies in building generational companies. Last but not least, we are grateful to our founders and LPs from around the globe for their continued trust.”
One Peak’s relationship-driven approach is augmented by PULSE, One Peak’s proprietary sourcing and business intelligence software platform. PULSE integrates with a plethora of data sources and continuously surfaces the most promising opportunities for new investments and bolt-on acquisitions for One Peak’s portfolio companies.
Strong Blue Chip Investor Base
Commitments to One Peak Growth III came from a diverse group of investors from the US and Europe, including blue chip university endowments, foundations, public pensions plans, insurance companies, asset managers, fund of funds, and family offices.
Proskauer Rose LLP and Van Campen Liem served as fund counsel to One Peak Growth III.
— Ends —
About One Peak
One Peak is a leading growth equity investment firm with approx. $2 billion in assets under management that invests in technology companies in the scale-up phase. One Peak provides growth capital, operating expertise and access to its extensive network to exceptional entrepreneurs, with a view to help transform innovative and rapidly growing businesses into lasting, category-defining leaders. One Peak’s investments include Ardoq, Brightflag, Coople, Cymulate, DataGuard, Deepki, DocPlanner, Emnify, HighQ, Infermedica, Keepit, Lucca, Neo4j, Orgvue, PandaDoc, Paysend, Quentic, Spryker Systems, and many more. To learn more, visit www.onepeak.tech.
Founder testimonials
“From the early days of our relationship, One Peak worked collaboratively with us to identify growth initiatives with the biggest impact. They helped us with revenue optimization, international expansion, M&A and the recruitment of world class talent. Above all, we really value the open and direct communication and are grateful for their trust, hard work, dedication, and passion to help us realize our vision.”
Mariusz Gralewski, Founder & CEO, DocPlanner
“One Peak has been a true value-add partner to us since day 1. They really are one of those rare investors that can zoom in and zoom out, talk big picture strategy and nitty-gritty operational details, and add value on the go-to-market side as well as challenge our thinking on product. Plus they are driven, passionate, have great clarity of thought, and are simply nice people – we genuinely enjoy the great cultural fit with the One Peak team.”
Emil Eifrem, Founder and CEO, Neo4j
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221205005103/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
